Biotech News
Medpace Holdings, Inc. Reports Third Quarter 2026 Results
Revenue of $716.0 million in the third quarter of 2026 increased 8.5% from revenue of $659.9 million for the comparable prior-year period, representing a backlog conversion rate of 23.8%. Net new business awards were $873.4 million in the third quarter of 2026, representing an increase of 10.6%
